Story perspectives

Ziihera Trial Success Boosts Jazz, Zymeworks Stocks

11/17/2025

35 4

Summary

Story summary

Jazz Pharmaceuticals and Zymeworks reported positive results for Ziihera in the HERIZON-GEA-01 trial, with the drug plus chemotherapy and BeOne's Tevimbra outperforming Roche's Herceptin in HER2-positive cancers.
Jazz plans to submit data to the U.S. FDA for approval in early 2026.
Analysts see Ziihera as a potential $1 billion-plus asset with strong breast cancer sales.
Jazz's shares surged over 18%, and Zymeworks' shares increased more than 30% after the announcement.

1 of 1

Story summary

Jazz Pharmaceuticals and Zymeworks reported positive results for Ziihera in the HERIZON-GEA-01 trial, with the drug plus chemotherapy and BeOne's Tevimbra outperforming Roche's Herceptin in HER2-positive cancers.
Jazz plans to submit data to the U.S. FDA for approval in early 2026.
Analysts see Ziihera as a potential $1 billion-plus asset with strong breast cancer sales.
Jazz's shares surged over 18%, and Zymeworks' shares increased more than 30% after the announcement.